{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:55:33Z","timestamp":1786449333243,"version":"build-2736575974"},"reference-count":52,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The aim of the present study was to determine the associations between the\n                    <jats:italic>MICB<\/jats:italic>\n                    genetic variability and the expression and the risk of development of post-transplant complications after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT recipients and their donors were genotyped for two\n                    <jats:italic>MICB<\/jats:italic>\n                    polymorphisms (rs1065075, rs3828903). Moreover, the expression of a soluble form of MICB was determined in the recipients' serum samples after transplantation using the Luminex assay. Our results revealed a favorable role of the\n                    <jats:italic>MICB<\/jats:italic>\n                    rs1065075\n                    <jats:italic>G<\/jats:italic>\n                    allele. Recipients with donors carrying this genetic variant were less prone to developing chronic graft-versus-host disease (cGvHD) when compared to recipients without any symptoms of this disease (41.41%\n                    <jats:italic>vs.<\/jats:italic>\n                    65.38%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.046). Moreover, the\n                    <jats:italic>MICB<\/jats:italic>\n                    rs1065075\n                    <jats:italic>G<\/jats:italic>\n                    allele was associated with a lower incidence of cytomegalovirus (CMV) reactivation, both as a donor (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.015) and as a recipient allele (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.039). The\n                    <jats:italic>MICB<\/jats:italic>\n                    rs1065075\n                    <jats:italic>G<\/jats:italic>\n                    variant was also found to be associated with decreased serum soluble MICB (sMICB) levels, whereas serum sMICB levels were significantly higher in recipients diagnosed with CMV infection (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0386) and cGvHD (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0008) compared to recipients without those complications. A protective role of the\n                    <jats:italic>G<\/jats:italic>\n                    allele was also observed for the rs3828903 polymorphism, as it was more frequently detected among donors of recipients without cGvHD (89.90%\n                    <jats:italic>vs.<\/jats:italic>\n                    69.23%;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.013).\n                    <jats:italic>MICB<\/jats:italic>\n                    genetic variants, as well as serum levels of sMICB, may serve as prognostic factors for the risk of developing cGvHD and CMV infection after allogeneic HSCT.\n                  <\/jats:p>","DOI":"10.2478\/aite-2024-0012","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:54:47Z","timestamp":1717750487000},"source":"Crossref","is-referenced-by-count":6,"title":["MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT"],"prefix":"10.2478","volume":"72","author":[{"given":"Jagoda","family":"Siemaszko","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Immunogenetics and Pharmacogenetics , Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Dratwa","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunogenetics and Pharmacogenetics , Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szeremet","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Majcherek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Sobczyk-Kruszelnicka","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Gliwice , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Fidyk","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Gliwice , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Solarska","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion Medicine , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Nasi\u0142owska-Adamska","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion Medicine , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Skowro\u0144ska","sequence":"additional","affiliation":[{"name":"Cell and Tissue Bank , University Medical Center in Gdansk , Gdansk , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bieniaszewska","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology , Medical University of Gdansk , Gdansk , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tomaszewska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine , Medical University of Warsaw , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz W.","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine , Medical University of Warsaw , Warsaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Gliwice , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bogunia-Kubik","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunogenetics and Pharmacogenetics , Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"2026060500074573261_j_aite-2024-0012_ref_001","doi-asserted-by":"crossref","unstructured":"Aguilar OA, Qualls AE, Gonzalez-Hinojosa MDR et al (2024) MICB genomic variant is associated with NKG2D-mediated acute lung injury and death. Am J Respir Crit Care Med 209:70\u201382. https:\/\/doi.org\/10.1164\/rccm.202303-0472OC","DOI":"10.1164\/rccm.202303-0472OC"},{"key":"2026060500074573261_j_aite-2024-0012_ref_002","doi-asserted-by":"crossref","unstructured":"Baek IC, Shin DH, Choi EJ et al (2018) Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients. Blood Cancer J 8:58. https:\/\/doi.org\/10.1038\/s41408-018-0092-5","DOI":"10.1038\/s41408-018-0092-5"},{"key":"2026060500074573261_j_aite-2024-0012_ref_003","doi-asserted-by":"crossref","unstructured":"Blunt MD, Khakoo SI (2023) Harnessing natural killer cell effector function against cancer. Immunother Adv 4:ltad031. https:\/\/doi.org\/10.1093\/immadv\/ltad031","DOI":"10.1093\/immadv\/ltad031"},{"key":"2026060500074573261_j_aite-2024-0012_ref_004","doi-asserted-by":"crossref","unstructured":"Bogunia-Kubik K, \u0141acina P (2021) Non-KIR NK cell receptors: Role in transplantation of allogeneic haematopoietic stem cells. Int J Immunogenet 48:157\u2013171. https:\/\/doi.org\/10.1111\/iji.12523","DOI":"10.1111\/iji.12523"},{"key":"2026060500074573261_j_aite-2024-0012_ref_005","doi-asserted-by":"crossref","unstructured":"Boutet P, Ag\u00fcera-Gonz\u00e1lez S, Atkinson S et al (2009) Cutting edge: The metalloproteinase ADAM17\/TNF-\u03b1-converting enzyme regulates proteolytic shedding of the MHC Class I-related chain B protein. J Immunol 182:49\u201353. https:\/\/doi.org\/10.4049\/jimmunol.182.1.49","DOI":"10.4049\/jimmunol.182.1.49"},{"key":"2026060500074573261_j_aite-2024-0012_ref_006","doi-asserted-by":"crossref","unstructured":"Carapito R, Aouadi I, Pichot A et al (2020) Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. Bone Marrow Transplant 55:1367\u20131378. https:\/\/doi.org\/10.1038\/s41409-020-0886-5","DOI":"10.1038\/s41409-020-0886-5"},{"key":"2026060500074573261_j_aite-2024-0012_ref_007","doi-asserted-by":"crossref","unstructured":"Chitadze G, Bhat J, Lettau M et al (2013) Generation of soluble NKG2D ligands: Proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 78:120\u2013129. https:\/\/doi.org\/10.1111\/sji.12072","DOI":"10.1111\/sji.12072"},{"key":"2026060500074573261_j_aite-2024-0012_ref_008","doi-asserted-by":"crossref","unstructured":"Doubrovina ES, Doubrovin MM, Vider E et al (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171:6891\u20136899. https:\/\/doi.org\/10.4049\/jimmunol.171.12.6891","DOI":"10.4049\/jimmunol.171.12.6891"},{"key":"2026060500074573261_j_aite-2024-0012_ref_009","doi-asserted-by":"crossref","unstructured":"Eberhardt KA, Jung V, Knops E et al (2023) CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant 58:639\u2013646. https:\/\/doi.org\/10.1038\/s41409-023-01944-2","DOI":"10.1038\/s41409-023-01944-2"},{"key":"2026060500074573261_j_aite-2024-0012_ref_010","doi-asserted-by":"crossref","unstructured":"Faridah IN, Dania H, Maliza R et al (2023) Genetic association studies of MICB and PLCE1 with severity of dengue in Indonesian and Taiwanese populations. Diagnostics 13:3365. https:\/\/doi.org\/10.3390\/diagnostics13213365","DOI":"10.3390\/diagnostics13213365"},{"key":"2026060500074573261_j_aite-2024-0012_ref_011","doi-asserted-by":"crossref","unstructured":"Farzad F, Yaghoubi N, Jabbari-Azad F et al (2022) Prognostic value of serum MICA levels as a marker of severity in COVID-19 patients. Immunol Invest 51:1856\u20131866. https:\/\/doi.org\/10.1080\/08820139.2022.2069035","DOI":"10.1080\/08820139.2022.2069035"},{"key":"2026060500074573261_j_aite-2024-0012_ref_012","doi-asserted-by":"crossref","unstructured":"Fuerst D, Neuchel C, Niederwieser D et al (2016) Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. Blood 128:3169\u20133176. https:\/\/doi.org\/10.1182\/blood-2016-05-716357","DOI":"10.1182\/blood-2016-05-716357"},{"key":"2026060500074573261_j_aite-2024-0012_ref_013","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Cruz C, Repiso T, Ferr\u00e1ndiz-Pulido C et al (2023) Risk factors and clinical characteristics of acute and chronic cutaneous graft-versus-host disease in pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Dermatol 40:1077\u20131080. https:\/\/doi.org\/10.1111\/pde.15447","DOI":"10.1111\/pde.15447"},{"key":"2026060500074573261_j_aite-2024-0012_ref_014","doi-asserted-by":"crossref","unstructured":"Goulding J, Yeh WI, Hancock B et al (2023) A chimeric antigen receptor uniquely recognizing MICA\/B stress proteins provides an effective approach to target solid tumors. Med 4:457\u2013477.e8. https:\/\/doi.org\/10.1016\/j.medj.2023.04.004","DOI":"10.1016\/j.medj.2023.04.004"},{"key":"2026060500074573261_j_aite-2024-0012_ref_015","doi-asserted-by":"crossref","unstructured":"Groh V, Wu J, Yee C et al (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734\u2013738. https:\/\/doi.org\/10.1038\/nature01112","DOI":"10.1038\/nature01112"},{"key":"2026060500074573261_j_aite-2024-0012_ref_016","doi-asserted-by":"crossref","unstructured":"Holdenrieder S, Stieber P, Peterfi A et al (2006a) Soluble MICA in malignant diseases. Int J Cancer 118:684\u2013687. https:\/\/doi.org\/10.1002\/ijc.21382","DOI":"10.1002\/ijc.21382"},{"key":"2026060500074573261_j_aite-2024-0012_ref_017","doi-asserted-by":"crossref","unstructured":"Holdenrieder S, Stieber P, Peterfi A et al (2006b) Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 55:1584\u20131589. https:\/\/doi.org\/10.1007\/s00262-006-0167-1","DOI":"10.1007\/s00262-006-0167-1"},{"key":"2026060500074573261_j_aite-2024-0012_ref_018","doi-asserted-by":"crossref","unstructured":"Holtick U, Quignot N, Kapso-Kapnang R et al (2024) Clinical and economic burden associated with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in Germany. Transplant Proc 56:191\u2013200. https:\/\/doi.org\/10.1016\/j.transproceed.2023.11.032","DOI":"10.1016\/j.transproceed.2023.11.032"},{"key":"2026060500074573261_j_aite-2024-0012_ref_019","doi-asserted-by":"crossref","unstructured":"Isernhagen A, Malzahn D, Viktorova E et al (2015) The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation. EMBO Mol Med 7:1480\u20131502. https:\/\/doi.org\/10.15252\/emmm.201505246","DOI":"10.15252\/emmm.201505246"},{"key":"2026060500074573261_j_aite-2024-0012_ref_020","doi-asserted-by":"crossref","unstructured":"Ivanova M, Al Hadra B, Yordanov S et al (2021) Associations of high-resolution-typing-defined MICA and MICB polymorphisms, and the levels of soluble MICA and MICB with oral squamous cell carcinoma in Bulgarian patients. J Oral Pathol Med 50:758\u2013765. https:\/\/doi.org\/10.1111\/jop.13185","DOI":"10.1111\/jop.13185"},{"key":"2026060500074573261_j_aite-2024-0012_ref_021","doi-asserted-by":"crossref","unstructured":"Kaidun P, Holzmayer SJ, Greiner SM et al (2023) Targeting NKG2DL with bispecific NKG2D-CD16 and NKG2D-CD3 fusion proteins on triple-negative breast cancer. Int J Mol Sci 24:13156. https:\/\/doi.org\/10.3390\/ijms241713156","DOI":"10.3390\/ijms241713156"},{"key":"2026060500074573261_j_aite-2024-0012_ref_022","doi-asserted-by":"crossref","unstructured":"Kshersagar J, Damle MN, Bedge P et al (2022) Downregulation of MICA\/B tumor surface expressions and augmented soluble MICA serum levels correlate with disease stage in breast cancer. Breast Dis 41:471\u2013480. https:\/\/doi.org\/10.3233\/BD-220023","DOI":"10.3233\/BD-220023"},{"key":"2026060500074573261_j_aite-2024-0012_ref_023","doi-asserted-by":"crossref","unstructured":"Machuldova A, Houdova L, Kratochvilova K et al (2021) Single-nucleotide polymorphisms in MICA and MICB genes could play a role in the outcome in AML patients after HSCT. J Clin Med 10:4636. https:\/\/doi.org\/10.3390\/jcm10204636","DOI":"10.3390\/jcm10204636"},{"key":"2026060500074573261_j_aite-2024-0012_ref_024","doi-asserted-by":"crossref","unstructured":"Nagai K, Tawara T, Usui J et al (2022) Levels of soluble NKG2D ligands and cancer history in patients starting hemodialysis. Front Nephrol 2:875207. https:\/\/doi.org\/10.3389\/fneph.2022.875207","DOI":"10.3389\/fneph.2022.875207"},{"key":"2026060500074573261_j_aite-2024-0012_ref_025","doi-asserted-by":"crossref","unstructured":"Nuckel H, Switala M, Sellmann L et al (2010) The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24:1152\u20131159. https:\/\/doi.org\/10.1038\/leu.2010.74","DOI":"10.1038\/leu.2010.74"},{"key":"2026060500074573261_j_aite-2024-0012_ref_026","doi-asserted-by":"crossref","unstructured":"Onyeaghala G, Nelson HH, Thyagarajan B et al (2017) Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study. Mol Carcinog 56:2158\u20132164. https:\/\/doi.org\/10.1002\/mc.22667","DOI":"10.1002\/mc.22667"},{"key":"2026060500074573261_j_aite-2024-0012_ref_027","doi-asserted-by":"crossref","unstructured":"Ouni N, Ben Chaaben A, Ayari F et al (2020) MICA-129 Met\/Val polymorphism could be a genetic biomarker for familial breast cancer in the Tunisian population. Int J Immunogenet 47:406\u2013413. https:\/\/doi.org\/10.1111\/iji.12480","DOI":"10.1111\/iji.12480"},{"key":"2026060500074573261_j_aite-2024-0012_ref_028","doi-asserted-by":"crossref","unstructured":"Ouni N, Ben Chaaben A, Kablouti G et al (2017) MICA-129Met\/Val polymorphism is associated with early-onset breast cancer risk. Immunol Invest 46:603\u2013614. https:\/\/doi.org\/10.1080\/08820139.2017.1336175","DOI":"10.1080\/08820139.2017.1336175"},{"key":"2026060500074573261_j_aite-2024-0012_ref_029","doi-asserted-by":"crossref","unstructured":"Parmar S, Del Lima M, Zou Y et al (2009) Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114:2884\u20132887. https:\/\/doi.org\/10.1182\/blood-2009-05-223172","DOI":"10.1182\/blood-2009-05-223172"},{"key":"2026060500074573261_j_aite-2024-0012_ref_030","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Ciceri F et al (2023) Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT Activity Survey. Bone Marrow Transplant 58:647\u2013658. https:\/\/doi.org\/10.1038\/s41409-023-01943-3","DOI":"10.1038\/s41409-023-01943-3"},{"key":"2026060500074573261_j_aite-2024-0012_ref_031","doi-asserted-by":"crossref","unstructured":"Patil S, Schwarer T (2009) Natural killer cells \u2212 new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation. Intern Med J 39:639\u2013647. https:\/\/doi.org\/10.1111\/j.1445-5994.2009.02024.x","DOI":"10.1111\/j.1445-5994.2009.02024.x"},{"key":"2026060500074573261_j_aite-2024-0012_ref_032","doi-asserted-by":"crossref","unstructured":"Petersdorf EW, McKallor C, Malkki M et al (2023) Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation. Blood Adv 7:2888\u20132896. https:\/\/doi.org\/10.1182\/bloodadvances.2022008922","DOI":"10.1182\/bloodadvances.2022008922"},{"key":"2026060500074573261_j_aite-2024-0012_ref_033","doi-asserted-by":"crossref","unstructured":"Peterson EE, Barry KC (2021) The natural killer-dendritic cell immune axis in anti-cancer immunity and immunotherapy. Front Immunol 11:621254. https:\/\/doi.org\/10.3389\/fimmu.2020.621254","DOI":"10.3389\/fimmu.2020.621254"},{"key":"2026060500074573261_j_aite-2024-0012_ref_034","doi-asserted-by":"crossref","unstructured":"Prokopeva AE, Emene CC, Gomzikova MO (2023) Antitumor immunity: Role of NK cells and extracellular vesicles in cancer immunotherapy. Curr Issues Mol Biol 46:140\u2013152. https:\/\/doi.org\/10.3390\/cimb46010011","DOI":"10.3390\/cimb46010011"},{"key":"2026060500074573261_j_aite-2024-0012_ref_035","doi-asserted-by":"crossref","unstructured":"Raffaghello L, Prigione I, Airoldi I et al (2004) Downregulation and\/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6:558\u2013568. https:\/\/doi.org\/10.1593\/neo.04316","DOI":"10.1593\/neo.04316"},{"key":"2026060500074573261_j_aite-2024-0012_ref_036","doi-asserted-by":"crossref","unstructured":"Ribeiro CH, Kramm K, G\u00e1lvez-Jir\u00f3n F et al (2016) Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA\/B) in gastric cancer patients. Oncol Rep 35:1309\u20131317. https:\/\/doi.org\/10.3892\/or.2015.4510","DOI":"10.3892\/or.2015.4510"},{"key":"2026060500074573261_j_aite-2024-0012_ref_037","doi-asserted-by":"crossref","unstructured":"Salih HR, Goehlsdorf D, Steinle A (2006) Release of MICB molecules by tumor cells: Mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67:188\u2013195. https:\/\/doi.org\/10.1016\/j.humimm.2006.02.008","DOI":"10.1016\/j.humimm.2006.02.008"},{"key":"2026060500074573261_j_aite-2024-0012_ref_038","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Cerrillo I, Calzada-Fraile D, Triguero-Mart\u00ednez A et al (2023) MICa\/b-dependent activation of natural killer cells by CD64+ inflammatory type 2 dendritic cells contributes to autoimmunity. EMBO J 42:e113714. https:\/\/doi.org\/10.15252\/embj.2023113714","DOI":"10.15252\/embj.2023113714"},{"key":"2026060500074573261_j_aite-2024-0012_ref_039","doi-asserted-by":"crossref","unstructured":"Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K (2021) NKG2D natural killer cell receptor-a short description and potential clinical applications. Cells 10:1420. https:\/\/doi.org\/10.3390\/cells10061420","DOI":"10.3390\/cells10061420"},{"key":"2026060500074573261_j_aite-2024-0012_ref_040","doi-asserted-by":"crossref","unstructured":"Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K (2023) Activating NKG2C receptor: Functional characteristics and current strategies in clinical applications. Arch Immunol Ther Exp 71:9. https:\/\/doi.org\/10.1007\/s00005-023-00674-z","DOI":"10.1007\/s00005-023-00674-z"},{"key":"2026060500074573261_j_aite-2024-0012_ref_041","doi-asserted-by":"crossref","unstructured":"Spreu J, Stehle T, Steinle A (2006) Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their \u03b12 domains. J Immunol 177:3143\u20133149. https:\/\/doi.org\/10.4049\/jimmunol.177.5.3143","DOI":"10.4049\/jimmunol.177.5.3143"},{"key":"2026060500074573261_j_aite-2024-0012_ref_042","doi-asserted-by":"crossref","unstructured":"Sulaiman NY, Anuar NA, Arshad N et al (2024) CMV infection post allogeneic hematopoietic stem cell transplantation in a resource limited country. Indian J Hematol Blood Transfus 40:97\u2013102. https:\/\/doi.org\/10.1007\/s12288-023-01655-0","DOI":"10.1007\/s12288-023-01655-0"},{"key":"2026060500074573261_j_aite-2024-0012_ref_043","doi-asserted-by":"crossref","unstructured":"Suresh PK (2016) Membrane-bound versus soluble major histocompatibility complex Class I-related chain A and major histocompatibility complex Class I-related chain B differential expression: Mechanisms of tumor eradication versus evasion and current drug development strategies. J Cancer Res Ther 12:1224\u20131233. https:\/\/doi.org\/10.4103\/0973-1482.176169","DOI":"10.4103\/0973-1482.176169"},{"key":"2026060500074573261_j_aite-2024-0012_ref_044","doi-asserted-by":"crossref","unstructured":"Vela-Ojeda J, Perez-Retiguin FDC, Olivas-Bejarano AC et al (2021) Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma. Leuk Lymphoma 62:801\u2013809. https:\/\/doi.org\/10.1080\/10428194.2020.1852473","DOI":"10.1080\/10428194.2020.1852473"},{"key":"2026060500074573261_j_aite-2024-0012_ref_045","doi-asserted-by":"crossref","unstructured":"Wang CM, Tan KP, Jan Wu YJ et al (2021) MICA*019 allele and soluble MICA as biomarkers for ankylosing spondylitis in Taiwanese. J Pers Med 11:564. https:\/\/doi.org\/10.3390\/jpm11060564","DOI":"10.3390\/jpm11060564"},{"key":"2026060500074573261_j_aite-2024-0012_ref_046","unstructured":"Wang LP, Niu H, Xia YF et al (2015) Prognostic significance of serum sMICA levels in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 19:2226\u20132230"},{"key":"2026060500074573261_j_aite-2024-0012_ref_047","doi-asserted-by":"crossref","unstructured":"Wang Y, Li S, Chen C et al (2019) MICB*002 and MICB*014 protect against rheumatoid arthritis, whereas MICA*009 and MICA*A6 are associated with rheumatoid arthritis in a Hainan Han Chinese population. Int J Rheum Dis 22:90\u201395. https:\/\/doi.org\/10.1111\/1756-185X.13302","DOI":"10.1111\/1756-185X.13302"},{"key":"2026060500074573261_j_aite-2024-0012_ref_048","doi-asserted-by":"crossref","unstructured":"Wu JD, Higgins LM, Steinle A et al (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560\u2013568. https:\/\/doi.org\/10.1172\/JCI22206","DOI":"10.1172\/JCI200422206"},{"key":"2026060500074573261_j_aite-2024-0012_ref_049","doi-asserted-by":"crossref","unstructured":"Xu Z, Taylor JA (2009) SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 37(Web Server issue):W600-5. https:\/\/doi.org\/10.1093\/nar\/gkp290","DOI":"10.1093\/nar\/gkp290"},{"key":"2026060500074573261_j_aite-2024-0012_ref_050","doi-asserted-by":"crossref","unstructured":"Yu P, Zhu Q, Chen C et al (2017) Association between major histocompatibility complex Class I chain-related gene polymorphisms and susceptibility of systemic lupus erythematosus. Am J Med Sci 354:430\u2013435. https:\/\/doi.org\/10.1016\/j.amjms.2017.06.003","DOI":"10.1016\/j.amjms.2017.06.003"},{"key":"2026060500074573261_j_aite-2024-0012_ref_051","doi-asserted-by":"crossref","unstructured":"Zingoni A, Vulpis E, Cecere F et al (2018) MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma. Front Immunol 9:926. https:\/\/doi.org\/10.3389\/fimmu.2018.00926","DOI":"10.3389\/fimmu.2018.00926"},{"key":"2026060500074573261_j_aite-2024-0012_ref_052","doi-asserted-by":"crossref","unstructured":"Zocchi MR, Camodeca C, Nuti E et al (2015) ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology 5:e1123367. https:\/\/doi.org\/10.1080\/2162402X.2015.1123367","DOI":"10.1080\/2162402X.2015.1123367"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aite-2024-0012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:08:10Z","timestamp":1780618090000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aite-2024-0012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,7]]},"published-print":{"date-parts":[[2024,1,1]]}},"alternative-id":["10.2478\/aite-2024-0012"],"URL":"https:\/\/doi.org\/10.2478\/aite-2024-0012","relation":{},"ISSN":["1661-4917"],"issn-type":[{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"20240012"}}